Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP∼T-HBs) combination vaccine

Vaccine

Volumn 25, Issue 43, 2007, Pages 7549-7558

  Stojanov, S ^a   Liese, J G ^a   Belohradsky, B H ^a   Vandermeulen, C ^b   Hoppenbrouwers, K ^b   Van der Wielen, M ^c   Van Damme, P ^c   Georges, B ^d   Dupuy, M ^d   Scemama, M ^d   Watson, M ^d   Fiquet, A ^d   Stek, J E ^e   Golm, G T ^e   Schodel F P ^e   Kuter, B J ^e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d SANOFI PASTEUR   (France)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Concomitant use; Hepatitis A; HEXAVAC ; Hexavalent; Immunization; Infant; Vaccines; VAQTA

Indexed keywords

ANTIGEN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DOSE RESPONSE; DRUG DOSE REGIMEN; HAEMOPHILUS INFLUENZAE; HEPATITIS A; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE EDEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MULTICENTER STUDY; POLIOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SERUM; TETANUS;

AGE FACTORS; CHILD, PRESCHOOL; FEMALE; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MALE; VACCINES, COMBINED;

EID: 34848836066     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.028     Document Type: Article

References (23)

1. Centers for Disease Control (CDC). Pertussis-United States, 1982 and 1983. MMWR 33 (1984) 573-575
2. Broome C.V., Preblud S.R., Bruner B., McGowan J.E., Hayes P.S., Harris P.P., et al. Epidemiology of pertussis, Atlanta, 1977. J Pediatr 98 (1981) 362-367
3. Cherry J.D. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 14 (1984) 1-78
4. Cherry J.D., Brunell P.A., Golden G.S., and Karzon D.T. Report of the task force on pertussis and pertussis immunization. Pediatrics Suppl (1988) 939-984
5. Romanus V., Jonsell R., and Bergquist S.O. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 6 (1987) 364-371
6. Edwards K.M., and Decker M.D. Combination vaccines: hope and challenges. Pediatr Infect Dis J 13 (1994) 345-347
7. Pichichero M.E. New combination vaccines. Childhood immun 47 (2000) 407-426
8. Jacobsen K.H., and Koopman J.S. Changing hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 133 (2004) 1005-1022
9. ACIP. Prevention of hepatitis A through active or passive immunization. MMWR 45 RR-15 (1996) 30
10. Vranckx R. Hepatitis A virus infections in Belgian children. Infection 21 (1993) 168-170
11. Beutels M., Van Damme P., Vranckx R., and Meheus A. The shift in prevalence of hepatitis A immunity in Flanders, Belgium. Acta Gastroenterol Belg LXI (1999) 4-7
12. Bölke E., and Flehmig B. New epidemiological patterns of Hepatitis A and B infections in Germany. Zbl Hyg 196 (1995) 511-514
13. Werzberger A., Mensch B., Kuter B., Brown L., Lewis J., Sitrin R., et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 327 (1992) 453-457
14. Innis B.L., Snitbhan R., Kunasol P., Laorakpongse T., Poopatanakool W., Kozik C.A., et al. Protection against hepatitis A by an inactivated vaccine. JAMA 271 (1994) 28-34
15. Lieberman J.M., Chang S.J., Patridge S., Hollister J.C., Kaplan K.M., Jensen E.H., et al. Kinetics of maternal hepatitis A antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 21 (2002) 347-348
16. Dagan R., Amir J., Mijalovsky A., Kammanavitch I., Bar-Yochai A., Thoelen S., et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 19 11 (2000) 1045-1052
17. Letson G.W., Shapiro C.N., Kuehn D., Gardea C., Welty T.K., Krause D.S., et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 144 3 (2004) 327-332
18. Mallet E., Staub T., Schödel F., Chryssomalis G., Hoffenbac A., and Scemama M. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 19 (2000) 1119-1127
19. Mallet E, Staub T, Schödel F, Chryssomalis G, Hoffenbach A, Scemama M. Safety and immunogenicity of a booster dose of the liquid hexavalent vaccine [DTaP-IPV-Hib-HB, HEXAVAC.] in 12-18 months old toddlers. Abst. ESPID, Istanbul, May 2001.
20. Liese J.G., Stojanov S., Berut F., Minini P., Harzer E., Jow S., et al. Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP∼T-HBs) administered at 2, 4, 6 and 12-14 months of age. Vaccine 20 (2002) 448-454
21. Block S.L., Hedrick J.A., Tyler R.D., Smith R.A., Calandra G., Patterson C., et al. Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children. Pediatr Infect Dis J 12 12 (1993) 976-980
22. Werzberger A., Kuter B., and Nalin D. Six years' follow-up after hepatitis A vaccination. NEJM 338 16 (1998) 1160
23. Lagos R., Munoz A., Dumas R., Pichon S., Zambrano B., Levine M., et al. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies. Vaccine 21 (2003) 3730-3733